**Partner’s info collection form**

Call/topic: **HORIZON-WIDERA-2025-01-ACCESS-01**

Proposal acronym: **SMART**

Contents

[Administrative Info 1](#_Toc128729754)

[Departments carrying out the proposed work 2](#_Toc128729755)

[Main contact person 3](#_Toc128729756)

[Researchers involved in the proposal 4](#_Toc128729757)

[Role of Participating organization in the project *(more than one options allowed)*: 5](#_Toc128729758)

[List of up to 5 publications, datasets, software, goods, services, or any other achievements relevant to the call content. 5](#_Toc128729759)

[List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal 6](#_Toc128729760)

[Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work 6](#_Toc128729761)

[Gender Equality Plan 6](#_Toc128729762)

# Administrative Info

|  |  |
| --- | --- |
| **PIC[[1]](#footnote-1): PIC 998058221** | **Legal Name of entity: University of Pernambuco**  **Acronym of legal entity: UPE** |
| **Country: Brazil** | **Official Logo (high resolution):** |

# Departments carrying out the proposed work

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| *The information serves mainly statistical purposes. For determining the eligibility of the proposal, the official address of the organisation is taken into account.*  **Department 1** | | | | |  |
| Department name |  | | | not applicable | |
|  | Same as organisation address | | |  | |
| Street | *Agamenon Magalhães Avenue* | | | Ues | |
|  | | | | | |
| Town | *Recife* | | |  | |
|  | | | | | |
| Postcode | *50100-130* | |  | | |
|  | | | | | |
| Country | *Brazil* | | |  | |
|  | | | | | |
| *Links with other participants*  *Please indicate if there are dependencies with other participants of the proposal.*  *Two participants (legal entities) are dependent on each other where there is a controlling relationship between them:*  *\* A legal entity is under the same direct or indirect control as another legal entity;or*  *\* A legal entity directly or indirectly controls another legal entity;or*  *\* A legal entity is directly or indirectly controlled by another legal entity.Control:*  *Legal entity A controls legal entity B if:*  *\* A, directly or indirectly, holds more than 50% of the nominal value of the issued share capital or a majority of the voting rights of the shareholders or associates of B, or*  *\* A, directly or indirectly, holds in fact or in law the decision-making powers in B.*  *The following relationships between legal entities shall not in themselves be deemed to constitute controlling relationships:*  *(a) the same public investment corporation, institutional investor or venture-capital company has a direct or indirect holding of more than 50 % of the nominal value of the issued share capital or a majority of voting rights of the shareholders or associates;*  *(b) the legal entities concerned are owned or supervised by the same public body.* | | | | | |  |
| ***Type of link*** | | ***Participant*** | | | |
| *[*Same group*]*  *[*Controls*]*  *[*Is controlled by*]* | | ***www.upe.br*** | | | |

# Main contact person

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| *It is the main scientist or team leader in charge of the proposal for the participant. For participant number 1 (the coordinator), this will be the person the EU services will contact concerning this proposal (e.g. for additional information, invitation to hearings, sending of evaluation results, convocation to negotiations). The data in blue is read-only. Details (name, first name and e-mail) of Main Contact persons should be edited in Step 4 of the Submission wizard.* | | | | | | | | | | | | | |
| Title: | | PhD | | Gender: | | | | Woman | Man | | | | Non binary |
|  | | | | | | | | | | | | | |
| First name: Maria Tereza  E-mail: tereza.cartaxo@upe.br | | | | | | Last name: Cartaxo Muniz | | | | | | | |
|  | | | | | | | | | | | | | |
| Position in org. | | *Master and Doctorate Program Coordenator and Researcher* | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Department | | Master and Doctorate Program in Aplied Molecular and Biological Sciences – Biologicals Sciences Institute | | | | | | | | | | Same as organisation | |
|  | | | Same as organisation address | | | | | | | |  | | |
| Street | | Arnóbio Marques street | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Town | | Recife | | | | | | Post code | 50100-130 | | |  | |
|  | | | | | | | | | | | | | |
| Country | | Brazil | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
| Website | |  | | | | | | | | | |  | |
|  | | | | | | | | | | | | | |
|  | Phone 1 | +5581982066802 | | | Phone 2 | | +558131833316 | | |  | |  | |
| *Other contact persons* | |  | | |  | |  | | |  | |  | |
| **First name** | | **Last name** | | | | | **e-mail** | | | | | **Phone** | |
| Maria Tereza | | Cartaxo Muniz | | | | | Tereza.cartaxo@upe.br | | | | | +5581982066802 | |
| Rosana Anita | | Da silva Fonseca | | | | | Rosana.fonseca@upe.br | | | | | +55 81 9925-1666 | |

# Researchers involved in the proposal

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ***Please, include also the main contact person, if a researcher*** | | | | | | | | | |
| **Title** | **First Name** | **Last Name** | **Gender** | **Nationality** | **E-mail** | **Career stage[[2]](#footnote-2)** | **Role of researcher (in the project)** | **Reference Identifier** | **Type of identifier** |
| Dr  Mr  Ms  Mrs  Prof | Maria Tereza | Cartaxo Muniz | Woman  Man  Non-binary | Brazil | Tereza.cartaxo@upe.br | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0001-9498-5223 | ORCID  Researcher Id  Other - specify |
| Dr  Mr  Ms  Mrs  Prof | Rosana Anita | Da silva Fonseca | Woman  Man  Non-binary | Brazil | Rosana.fonseca@upe.br | Cat A  Cat B  Cat C  Cat D | Leading  Team member | 0000-0002-9043-3998 | ORCID  Researcher Id  Other - specify |

# Role of Participating organization in the project *(more than one options allowed)*:

|  |
| --- |
| Project management;  Communication, dissemination and engagement;  Provision of research and technology infrastructure;  Co-definition of research and market needs;  Civil society representative;  Policy maker or regulator, incl. standardization body;  Research performer;  Technology developer;  Testing/validation of approaches and ideas;  Prototyping and demonstration;  IPR management incl. technology transfer;  Public procurer of results;  Private buyer of results;  Finance provider (public or private);  Education and training;  Contributions from the social sciences or/and the humanities;  Other;  If other, please specify: (Maximum number of characters allowed: 50) |

# List of up to 5 publications, datasets, software, goods, services, or any other achievements relevant to the call content.

|  |  |
| --- | --- |
| **Type of achievement** | **Short Description (Max 500 characters)** |
| **[Publication]**  **[Dataset]**  **[Software]**  **[Good]**  **[Service]**  **[Other achievement]** | ***Key elements of the achievement, including a short qualitative assessment of its impact and (where available) its digital object identifier (DOI) or other type of persistent identifier (PID).***  ***Publications, in particular journal articles, are expected to be open access. Datasets are expected to be FAIR and ‘as open as possible, as closed as necessary’.*** |
| **Publication – Chapter book** | **DEVELOPMENT OF A VIRTUAL REALITY PROTOTYPE FOR USE IN A HOSPITAL CLASSROOM OF CHILDREN AND ADOLESCENTS WITH CANCER. ISBN: 978-84-1070-251-6** |
| **Publication - article** | ***EFICÁCIA DA VOLTAMETRIA CÍCLICA E VOLTAMETRIA ONDA QUADRADA PARA***  ***DETECÇÃO DE ANFETAMINA E DERIVADOS: UMA REVISÃO SISTEMÁTICA. LINK:*** [***HTTP://DX.DOI.ORG/10.15260/RBC.V0I0.00***](http://dx.doi.org/10.15260/rbc.v0i0.00) |
| **Publication Article** | ***QUANTITATIVE URINE SPOT MICROSAMPLES FOR THE CHIRAL ANALYSIS OF CLENBUTEROL BY CAPILLARY ELECTROKINETIC CHROMATOGRAPHY. Link:*** [***10.1016/j.microc.2025.112940***](file:///C:\Users\Tereza%20cartaxo\OneDrive\Área%20de%20Trabalho\Tereza%20Cartaxo\HORIZON%202025\SMART%20admin%20document%20Horizon%20MTCM_23_07_25.docx) |
| **Publication Article** | ***ANALOGOS DA FALACIA DO ADVOGADO E DO PROMOTOR NO TESTE DE PATERNIDADE. Link:*** [***10.15260/rbc.v13i3.784***](file:///C:\Users\Tereza%20cartaxo\OneDrive\Área%20de%20Trabalho\Tereza%20Cartaxo\HORIZON%202025\SMART%20admin%20document%20Horizon%20MTCM_23_07_25.docx) |
| **Publication Article** | ***IT WAS NOT POSSIBLE TO DETECT <I>BRAF V600E</I> MUTATION IN CIRCULATING CELL-FREE DNA FROM PATIENTS WITH AMELOBLASTOMA: A DIAGNOSTIC ACCURACY STUDY. Link:*** [***10.1111/jop.13529***](file:///C:\Users\Tereza%20cartaxo\OneDrive\Área%20de%20Trabalho\Tereza%20Cartaxo\HORIZON%202025\SMART%20admin%20document%20Horizon%20MTCM_23_07_25.docx) |

# List of up to 5 most relevant previous projects or activities, connected to the subject of this proposal

|  |  |
| --- | --- |
| **Name of the project or activity** | **Short Description (Max 500 characters)** |
| **AVALIAÇÃO DE IMPRESSÃO DIGITAL LATENTE ATRAVÉS DA ESPECTROMETRIA DE MASSAS POR IONIZAÇÃO E DESSORÇÃO A LASER ASSISTIDA POR MATRIZ PARA APLICAÇÃO FORENSE.** | STANDARDIZATION OF MASS SPECTOMETER - MS FOR DETECTING DRUGS IN ADHESIVES - Steps developed so far: adhesives were fortified with cocaine and THC standards. After this step, the material was extracted in methanol and then injected into the mass spectrometer to identify the peaks of the drug metabolites. The analysis of the same metabolites will also be performed on glass slides where there are fingerprints. |
| **DEVELOPMENT OF A VIRTUAL REALITY PROTOTYPE FOR USE IN A HOSPITAL CLASSROOM OF CHILDREN AND ADOLESCENTS WITH CANCER** | Becoming ill in childhood can provide various kinds of distress, causing physical and psychosocial damage. Hospital classes were created, aiming at not interrupting the schooling of hospitalized children and adolescents. The use of technology in pedagogical care in the hospital is seen as something that can mitigate illness restraint and enhance the learning of students undergoing hospital treatment. |
| **COMPARATIVE STUDY, USING BIOLOGICAL SAMPLES FROM CHILDREN DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), WHICH WILL BEGIN IN MAY 2021, AIMING AT THE EVALUATION OF AN AUTOMATED METHOD (PICKCELLS SOLUTION) FOR THE DETECTION OF IMMATURE CELLS IN MICROSCOPIC SLIDES OF PERIPHERAL BLOOD (BLOOD COUNT) AND BONE MARROW MATERIAL.** | Acute lymphoblastic leukemia (ALL) accounts for approximately 80% of childhood leukemias. Cell proliferation and immaturity are assessed using a myelogram. Classification of some cases is difficult, demonstrating the need for new parameters to standardize diagnosis. This study aims to identify the important cytomorphological characteristics for automated ALL analysis by comparing the specificities of slide image banks and the algorithms used in automated analysis. |
| **TRANFORMANDO LA EDICACIÓN: TECNOLOGÍA, EDUCACIÓN E SOCIEDAD AN LA ERA DIDITAL** | Project aimed at developing applications and methods for teaching in the health field |
| **PANORAMA DE LAS POLÍTICAS PÚBLICAS EN LA UNIVERSIDAD DE PERNAMBUCO: UN ANÁLISIS DE LAS CONTRIBUCIONES LOGRADAS CON EL PROYECTO SOLIDARIS Y LAS PERSPECTIVAS FUTURAS PARA CONSOLIDAR LAS ACCIONES DE INCLUSIÓN** | These projects seek to foster key competencies in the university community for the development of active citizenship and are aimed at driving future changes, such as the creation of a service and support center for students belonging to historically excluded groups. |

# Description of any significant infrastructure and/or any major items of technical equipment, relevant to the proposed work

|  |  |
| --- | --- |
| **Name of infrastructure or equipment** | **Short Description (Max 300 characters)** |
| **ABI Prism 3500 and NANO-MIN101B GENE** | **MULTIUSER HEALTH LABORATORY- TO IDENTIFY NUCLEIC ACIDS SEQUENCE -SEQUENCING AND EXPRESSION PLATFORM, ANALYTICAL CENTER** |
| **EXTRATOR AUTOMATICO DE ACIDOS NUCLEICOS**  **EXTRACTA® 32 (IVD)** | **MULTIUSER HEALTH LABORATORY – TO EXTRACT NUCLEIC ACIDS – ADN AND ARN** |
| **POTENCIOSTATO/GALVANOSTATO, MODEL PGSTAT204** | ***NANOBIOANALYSIS LABORATORY - ELECTROCHEMICALANALYSIS AND DEVELOPMENT OF BIOSENSORS FOR RAPID TESTING IN HUMAN SERUM FOR THE DIAGNOSIS AND CONTROL OF IMPORTANT PATHOLOGIES. SYNTHESIS OF METALLIC NANOPARTICLES FOR THE CONSTRUCTION OF MORE SENSITIVE BIOSENSORS*** |
| **HPLC AGILENT 1200** | **MULTIUSER HEALTH LABORATORY: HIGH PERFORMANCE LIQUID CHROMATOGRAPH HAS A DEGASSER, BINARY PUMP, AUTOMATIC INJECTOR WITH CAPACITY FOR 100 2 ML VIALS, OVEN AND REFRACTIVE INDEX (RID), FLUORESCENCE (FLD) AND DIODE ARRAY (DAD) DETECTORS.** |
| ***AMPLIO 96 (LOCCUS)*** | **MULTIUSER HEALTH LABORATORY: REAL-TIME PCR IN A 96-WELL PLATE FOR REAL-TIME FLUORESCENCE DETECTION, QUANTIFICATION, AND MONITORING. IT HAS WIDE DYNAMIC RANGE, EQUIPPED WITH 6 FLUORESCENCE CAPTURE FILTERS.** |
| ***ESPECTROFOTÔMETRO DE MICROPLACA EPOCH BIOTEK*** | **MULTIUSER HEALTH LABORATORY: *UV-VIS ABSORBANCE READINGS AT ANY WAVELENGTH (200–999 NM), WITHOUT THE NEED FOR FILTERS, ON A VARIETY OF MICROPLATE FORMATS. THE EQUIPMENT IS OPERATED USING GEN5 SOFTWARE, WHICH HAS AN INTUITIVE, EASY-TO-PROGRAM INTERFACE AND POWERFUL DATA ANALYSIS THROUGH AUTOMATED PROCESSING.*** |

# Gender Equality Plan

**Does the organization have a Gender Equality Plan (GEP) covering the elements listed below?**

**Yes / No**

**Yes**

[**https://www.upe.br/images/RESOLUCAO\_CONSUN\_N\_017\_2021.pdf**](https://www.upe.br/images/RESOLUCAO_CONSUN_N_017_2021.pdf)

**Minimum process-related requirements (building blocks) for a GEP**

**- Publication:** formal document published on the institution's website and signed by the top management

**- Dedicated resources:** commitment of human resources and gender expertise to implement it.

**- Data collection and monitoring:** sex/gender disaggregated data on personnel (and students for establishments concerned) and annual reporting based on indicators.

**- Training:** Awareness raising/trainings on gender equality and unconscious gender biases for staff and decision-makers.

**-** Content-wise, recommended areas to be covered and addressed via concrete measures and targets are:

**♦ work-life balance and organisational culture;**

**♦ gender balance in leadership and decision-making;**

**♦ gender equality in recruitment and career progression;**

**♦ integration of the gender dimension into research and teaching content;**

**♦ measures against gender-based violence including sexual harassment.**

# Involved Third Parties

|  |  |
| --- | --- |
| **Does the participant plan to subcontract**[[3]](#footnote-3) **certain tasks (please note that core tasks of the project should not be sub-contracted)** | **N** |
| If **yes**, please describe and justify the tasks to be subcontracted. | |
| **Does the participant envisage that part of its work is performed by Affiliated Entities**[[4]](#footnote-4) (**Article 8 of the Corporate Model Grant Agreement)** | **N** |
| If **yes**, please describe the third party, the link of the participant to the third party, and describe and justify the foreseen tasks to be performed by the third party. | |
| **Does the participant envisage the use of contributions in kind provided by third parties**[[5]](#footnote-5) **(Articles 9.2 of the Corporate Model Grant Agreement)** | **N** |
| If **yes**, please describe the third party(ies) and its/ their contribution(s). | |
| **Does the participant envisage that part of the work is performed by Associated partners**[[6]](#footnote-6) **(Article 9.1 of the Corporate Model Grant Agreement)?** | **N** |
| If **yes**, please describe the Associated Partner(s) and their contributions | |
| **Does the participant envisage that part of the work is performed by international organisations**[[7]](#footnote-7) **(Article 10.2 of the Corporate Model Grant Agreement)?** | **N** |
| If **yes**, please describe the International Partner(s) and their contributions | |

1. A Participant Identification Code (PIC) is **a 9-digit number that serves as a unique identifier for legal entities participating in European funding programmes**. A PIC number has no expiry date. If your organization does not have a PIC, you can get it [**here**](https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/how-to-participate/participant-register). [↑](#footnote-ref-1)
2. Career stages as defined in Frascati 2015 manual:

   **Category A –** Top grade researcher: the single highest grade/post at which research is normally conducted. Example: ‘Full professor’ or ‘Director of research’.

   **Category B** – Senior researcher: Researchers working in positions not as senior as top position but more senior than newly qualified doctoral graduates (IsCED level 8). Examples: ‘associate professor’ or ‘senior researcher’ or ‘principal investigator’.

   **Category C –** Recognised researcher: the first grade/post into which a newly qualified doctoral graduate would normally be recruited. Examples: ‘assistant professor’, ‘investigator’ or ‘post-doctoral fellow’.

   **Category D –** First stage researcher: Either doctoral students at the IsCED level 8 who are engaged as researchers, or researchers working in posts that do not normally require a doctorate degree. Examples: ‘PhD students’ or ‘junior researchers’ (without a PhD). [↑](#footnote-ref-2)
3. Subcontractors may participate in the action, if necessary for the implementation. Subcontractors must implement their action tasks in accordance with Article 11. The costs for the subcontracted tasks (invoiced price from the subcontractor) are eligible and may be charged by the beneficiaries, under the conditions set out in Article 6. The costs will be included in Annex 2 as part of the beneficiaries’ costs. [↑](#footnote-ref-3)
4. Affiliated entities can charge costs and contributions to the action under the same conditions as the beneficiaries and must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. Their costs and contributions will be included in Annex 2 and will be taken into account for the calculation of the grant. The beneficiaries must ensure that all their obligations under this Agreement also apply to their affiliated entities. The beneficiaries must ensure that the bodies mentioned in Article 25 (e.g. granting authority, OLAF, Court of Auditors (ECA), etc.) can exercise their rights also towards the affiliated entities. Breaches by affiliated entities will be handled in the same manner as breaches by beneficiaries. Recovery of undue amounts will be handled through the beneficiaries. If the granting authority requires joint and several liability of affiliated entities (see Data Sheet, Point 4.4), they must sign the declaration set out in Annex 3a and may be held liable in case of enforced recoveries against their beneficiaries (see Article 22.2 and 22.4). [↑](#footnote-ref-4)
5. Other third parties may give in-kind contributions to the action (i.e. personnel, equipment, other goods, works and services, etc. which are free-of-charge), if necessary for the implementation. Third parties giving in-kind contributions do not implement any action tasks. They may not charge costs or contributions to the action and the costs for the in-kind contributions are not eligible. [↑](#footnote-ref-5)
6. Associated partners must implement the action tasks attributed to them in Annex 1 in accordance with Article 11. They may not charge costs or contributions to the action and the costs for their tasks are not eligible. [↑](#footnote-ref-6)
7. Participants which are established in a non-EU country [↑](#footnote-ref-7)